SEC Comment Letter for NUGENEREX IMMUNO-ONCOLOGY, INC. (CIK 0001804585) — Sep 1, 2020
NUGENEREX IMMUNO-ONCOLOGY, INC. (CIK 0001804585)
Date: Sept. 1, 2020 · CIK: 0001804585 · Accession: 0000000000-20-008240
AI Filing Summary & Sentiment
File numbers found in text: 000-56153
Letter
United States securities and exchange commission logo September 1, 2020 Joseph Moscato Chief Executive Officer NuGenerex Immuno-Oncology, Inc. 10102 USA Today Way Miramar, FL 33025 Re:NuGenerex Immuno-Oncology, Inc. Registration Statement on Form 10-12G Filed March 12, 2020 File No. 000-56153 Dear Mr. Moscato: We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Jeffrey Wofford, Esq.
Show Raw Text
United States securities and exchange commission logo
September 1, 2020
Joseph Moscato
Chief Executive Officer
NuGenerex Immuno-Oncology, Inc.
10102 USA Today Way
Miramar, FL 33025
Re:NuGenerex Immuno-Oncology, Inc.
Registration Statement on Form 10-12G
Filed March 12, 2020
File No. 000-56153
Dear Mr. Moscato:
We have completed our review of your filing. We remind you that the company and its
management are responsible for the accuracy and adequacy of their disclosures, notwithstanding
any review, comments, action or absence of action by the staff.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Jeffrey Wofford, Esq.